Senate Leaders Warn DoD: Foreign Generic Drug Supply Chain Poses 'Existential Risk' to Military

Senate leaders are urging the Department of Defense to prioritize the purchase of generic drugs manufactured in the United States, warning that the country’s overreliance on foreign factories poses an “existential risk” to the military. In a letter last week, Sens. Rick Scott, R-Fla., and Kirsten Gillibrand, D-N.Y., asked Defense Department Secretary Pete Hegseth to provide information about drugs or key ingredients purchased from foreign sources and how long the department’s inventory would last if China restricted exports. They also sought details about whether the Food and Drug Administration had imposed any import bans on the department’s suppliers. The letter cited ProPublica reporting last year that found the FDA allowed dozens of foreign drugmakers, mostly in India and China, to continue sending generic medication to the U.S. even after the factories were banned because of serious safety and quality-control failures. Since 2013, ProPublica found, the FDA allowed more than 150 drugs or their ingredients into the United States from banned factories, including antibiotics, anti-seizure drugs and chemotherapy treatments. The agency has said that the exemptions helped prevent drug shortages and that factories were required to conduct extra quality testing with third-party oversight. “Exempting these drugs or facilities allows for substandard and potentially unsafe drugs to enter the U.S. market,” the senators wrote in their letter. “These exemptions can pose a threat to drug safety and national security.”